Home

Subscription

July 2017 issue

June 2017 issue

May 2017 issue

April 1, 2017 issue

March 2017 issue

February 2017 issue

January 2017 issue



BACK ISSUES

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006


2015 Issues

December 2015 Issue
• Feature: How Shall We Live?
• "Support Independents"
• Appreciation
• Indexes for Volume 6, 2011 through Volume 9, 2014
• Index for Volume 10, 2015


November 2015 Issue
• Feature: Medications that Must Be Available without a Prescription from a Pharmacist
• New Drug Review: Brexpiprazole (Rexulti – Otsuka)


October 2015 Issue
• Feature: The FTC should just say NO! to CVS acquiring Target pharmacies and to Walgreens acquiring Rite Aid!
• New Drug Review: Sacubitril/valsartan (Entresto – Novartis)


September 2015 Issue
• Feature: Daraprim – The Ultimate Drug Pricing Outrage?
• New Drug Review: Suvorexant (Belsomra – Merck)


August 2015 Issue
• Feature: CVS Recommendations about the Cholesterol Guidelines are Not Credible When Its Pharmacists Do Not Have Enough Staff and Time to Practice Optimally
• New Therapeutic Agents Marketed in the United States in 2014


July 2015 Issue
• Feature: Time Out!*
• New Drug Review: Edoxaban tosylate monohydrate (Savaysa – Daiichi-Sankyo)


March 2015 Issue
• Feature: PHARMACY'S VISION FOR 2015 [2004-2014 Rest in Peace]
• New Drug Review: Vorapaxar sulfate (Zontivity – Merck)


February 2015 Issue
• Feature: Drug Shortages and High-Priced Generics – Pharmacy Should Establish Our Own Generics Pharmaceutical Company!
• New Drug Review: Olodaterol hydrochloride (Striverdi Respimat – Boehringer Ingelheim)


January 2015 Issue
• Feature: Express Scripts Made the Wrong Formulary Decision that is a Disservice to its Customers
• New Drug Review: Ledipasvir/sofosbuvir (Harvoni – Gilead Sciences)
• New Drug Review: Ombitasvir, paritaprevir, ritonavir, dasabuvir sodium monohydrate (Viekira Pak – AbbVie)